TSE:PMN ProMIS Neurosciences (PMN) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About ProMIS Neurosciences Stock (TSE:PMN) 30 days 90 days 365 days Advanced Chart Ad Crypto 101 MediaTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… YES, I WANT THE #1 CRYPTO NOW Get ProMIS Neurosciences alerts:Sign Up Key Stats Today's Range N/A50-Day RangeC$6.00▼C$6.0052-Week Range N/AVolume19,701 shsAverage Volume3,327 shsMarket CapitalizationC$51.48 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.Read More… Trump’s Sending THIS Crypto Higher on Purpose (Ad)Discover the coin set to explode before 2025! Trump could trigger THIS crypto coin… YES, I WANT THE #1 CRYPTO NOW Receive PMN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ProMIS Neurosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address PMN Stock News HeadlinesProMIS Neurosciences reports Q3 EPS 31c vs (19c) last yearNovember 15, 2024 | markets.businessinsider.comProMIS Neurosciences Presents Positive Data from PMN310 Phase1a Clinical Trial at the 17th Clinical Trials on Alzheimer’s Disease ConferenceOctober 30, 2024 | finance.yahoo.comTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… November 21, 2024 | Crypto 101 Media (Ad)ProMIS Neurosciences, Inc. (PMN): Analysts Are Bullish On This Undervalued Canadian Stock NowOctober 13, 2024 | msn.comTargeting brain lesions with TMS shows promise in treating PTSD in veteransSeptember 27, 2024 | msn.comProMIS Neurosciences Inc.: ProMIS Neurosciences Announces Second Quarter 2024 Financial Results and Recent HighlightsAugust 9, 2024 | finanznachrichten.deBuy Rating on ProMIS Neurosciences Backed by Innovative Alzheimer’s Treatment and Strong FinancialsAugust 9, 2024 | markets.businessinsider.comAnaergia: Top 10 Undervalued Growth Stocks on TSX (ANRG)July 27, 2024 | theglobeandmail.comSee More Headlines PMN Stock Analysis - Frequently Asked Questions How do I buy shares of ProMIS Neurosciences? Shares of PMN stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. What other stocks do shareholders of ProMIS Neurosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that ProMIS Neurosciences investors own include CRISPR Therapeutics (CRSP), Aurora Cannabis (ACB), Keurig Dr Pepper (KDP), Biocept (BIOC), Onconova Therapeutics (ONTX), Spectra7 Microsystems (SEV) and TherapeuticsMD (TXMD). Industry, Sector and Symbol Stock ExchangeTSE SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolTSE:PMN Previous SymbolTSE:AMF CUSIPN/A CIKN/A Webwww.promisneurosciences.com Phone+1-416-8476898FaxN/AEmployees6Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)C($3.38) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeC$-20,930,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-837.71% Return on Assets-168.33% Debt Debt-to-Equity Ratio108.33 Current Ratio0.51 Quick Ratio1.30 Sales & Book Value Annual SalesC$7,558.00 Price / Sales0.00 Cash FlowN/A Price / Cash Flow14.07 Book ValueC($0.72) per share Price / BookN/AMiscellaneous Outstanding Shares8,580,000Free FloatN/AMarket CapC$51.48 million OptionableNot Optionable Beta1.19 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report This page (TSE:PMN) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProMIS Neurosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ProMIS Neurosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.